Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
33.33%
0%
33.33%
6 Months
-31.03%
0%
-31.03%
1 Year
-48.72%
0%
-48.72%
2 Years
-45.95%
0%
-45.95%
3 Years
-83.12%
0%
-83.12%
4 Years
-83.26%
0%
-83.26%
5 Years
-78.46%
0%
-78.46%
American Vietnamese Biotech, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-9.19%
EBIT Growth (5y)
-42.86%
EBIT to Interest (avg)
2.61
Debt to EBITDA (avg)
1.50
Net Debt to Equity (avg)
0.09
Sales to Capital Employed (avg)
0.14
Tax Ratio
58.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.68%
ROE (avg)
4.40%
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
NA
EV to EBIT
9.58
EV to EBITDA
3.44
EV to Capital Employed
0.08
EV to Sales
0.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.86%
ROE (Latest)
-0.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Jun 2023
Shareholding Compare (%holding) 
Majority shareholders
Non Institution
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
63,555.00
222,710.30
-71.46%
Operating Profit (PBDIT) excl Other Income
10,917.60
70,235.10
-84.46%
Interest
5,444.90
5,015.50
8.56%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3,387.00
67,285.40
-105.03%
Operating Profit Margin (Excl OI)
36.70%
282.60%
-24.59%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -71.46% vs 3,801.24% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is -105.03% vs 48.46% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
310,354.60
196,570.10
57.88%
Operating Profit (PBDIT) excl Other Income
19,689.90
54,174.50
-63.65%
Interest
19,650.50
23,353.30
-15.86%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-13,065.20
10,732.10
-221.74%
Operating Profit Margin (Excl OI)
-13.90%
165.20%
-17.91%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 57.88% vs -30.99% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -221.74% vs -80.98% in Dec 2023
About American Vietnamese Biotech, Inc. 
American Vietnamese Biotech, Inc.
Medical Specialties
American Vietnamese Biotech Incorporation (AmviBiotech) is a Vietnam-based company engaged in the pharmaceutical industry. The Company is involved in the manufacture of medicines, vaccines and biological products. It is also involved in the manufacture of rapid diagnostic tests and ELISA kits, as well as the trading of other medical equipment and tools. In addition, the Company is active in the manufacture of cosmetic, soaps, detergents and other polishing and cleaning products. Its other activities include real estate trading, financial investment and the manufacture of plastic products. As of December 31, 2012, the Company had one wholly owned subsidiary named American - Vietnamese Biology Company Limited.
Company Coordinates 
Company Details
So 1251 QL 14, thi xa Dong Xoai , HO CHI MINH None : None
Registrar Details






